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Both parity and oral contraceptive use are associated with elevated circulating levels of sex hormones, at least transiently, and with
increased risk of cervical cancer in human papillomavirus (HPV)-infected women. We directly evaluated whether elevations in the
physiologic levels of these hormones predispose to the development of cervical neoplasia. We identified 67 premenopausal and 43
postmenopausal women with cervical intraepithelial neoplasia 2, 3, or cervical cancer (XCIN2) diagnosed during enrollment of a
population-based cohort of 10077 women. Four controls, two chosen randomly and two chosen from women testing positive for
cancer-associated HPV, were matched to each case on menopausal status, age, days since last menses (pre), or years since
menopause (post). Sex hormone-binding globulin, oestradiol, oestrone, oestrone-sulphate, dehydroepiandrosterone sulphate, and
progesterone were measured in enrollment plasma. There was no consistent association between the sex hormones and risk of
XCIN2. Excluding cases with invasive disease had a minimal impact on results. Though this case–control study was based on a well-
defined population, it was limited by reliance on a single measure of hormone levels taken at the time of diagnosis. Nonetheless, our
results do not support the hypothesis that plasma levels of sex hormones have an important bearing on the risk of cervical neoplasia
in HPV-infected women.
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Research of the past two decades has established that infection
with oncogenic types of human papillomavirus (HPV) is the major
cause of cervical cancer (Bosch et al, 2002). Although infection
with HPV is common, relatively few infections persist and progress
to malignancy. Therefore, research has turned towards identifying
factors that work together with HPV to cause cervical cancer.
Among HPV-positive women, consistently identified risk factors
for cervical cancer include parity and long-term oral contraceptive
use (Bosch et al, 2002; Moreno et al, 2002; Munoz et al, 2002).
While the means by which these factors are associated with an
increase in risk is unclear, it could relate to elevated levels of
circulating hormones such as oestrogens and progesterone.
Evidence of a role for endogenous hormones in cervical
carcinogenesis deriving from a small epidemiologic study (Zheng,
1990), and several laboratory studies of cervical cell lines and
HPV-16 transgenic mice (Mitrani-Rosenbaum et al, 1989; Pater
et al, 1994; Arbeit et al, 1996; Chen et al, 1996; Elson et al, 2000),
stimulated us to conduct a population-based case–control study to
examine the association between plasma levels of several
hormones (oestradiol, oestrone, oestrone sulphate, dehydroepian-
drosterone sulphate (DHEAS), progesterone), sex hormone-bind-
ing globulin (SHBG), and the risk of cervical cancer.
MATERIALS AND METHODS
Guanacaste cohort
Study subjects were drawn from the enrollment phase of a
population-based cohort study of cervical cancer that was
launched in Guanacaste, Costa Rica, in 1993. The Guanacaste
cohort has been described in detail (Herrero et al, 1997). The study
was conducted after approval by the NCI and local institutional
review boards, and all participants provided written informed
consent. Censal segments were used as the primary sample unit for
selection of participants, and 11742 women over 18 years of age
were enumerated (Figure 1). In addition, since the expected
number of invasive cervical cancer cases was small, all identified
residents of Guanacaste newly diagnosed with invasive cervical
cancer (n¼31) during enrollment of the study in the three
regional hospitals or referred to three tertiary care hospitals in San
Jose were invited to participate in the study.
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interview completed a brief interview that collected information on
the socioeconomic, demographic, sexual, reproductive, medical,
and smoking history. A total of 8582 sexually active women with
an intact uterus underwent a pelvic exam, followed by a cervical
scrape with a Cervex brush that was used to prepare a conventional
Pap smear. Residual cells remaining on the sampling device were
rinsed in PreservCyt (Boxborough, MA, USA) and used to prepare
a ThinPrep slide. A second exfoliative sample was collected in
specimen transport medium (STM, Digene, Silver Spring, MD,
USA) for HPV testing. Then, the cervix was painted with 5% acetic
acid and two cervigrams (photographic images) were obtained.
Women with cervical abnormalities detected by visual inspec-
tion, cytology or cervicography, as well as a 2% random sample of
the study population were referred for colposcopy and biopsy if
indicated. The final diagnoses were based on review of cytology,
cervigram, and histology. Final diagnoses included 40 women (28
identified in hospitals) with invasive cervical cancer (39 histolo-
gically confirmed, one surgically evident), 119 with histologically
confirmed high-grade cervical intraepithelial neoplasia (CIN 2-3),
nine with CIN 2-3 defined by reviewed and confirmed cytology,
189 with low-grade cervical intraepithelial lesions (CIN 1), 661 with
equivocal lesions, and 7564 with normal final diagnoses.
In all, 99.2% of the women interviewed donated a 15ml blood
sample that was collected in a heparinised tube and kept at 1–41C
in coolers in the field. The samples were transported daily to field
stations, where the plasma was isolated and frozen in aliquots at
 301C. Weekly, the samples were transported on ice packs to San
Jose, stored at  701C, and sent on dry ice to the NCI repository in
Maryland, where they were stored long term at  701C.
Cervical cells were tested for the presence of HPV using PCR
with MY09/MY11 L1 consensus primers (Herrero et al, 2000).
Laboratory personnel were blinded to the case–control status of
samples. At the time HPV-positive controls were selected for the
current case–control study, a total of 5703 subjects, 57.2% of the
subjects with blood samples collected, had been tested for HPV
using PCR. A total of 707 (12.4% of those tested) subjects tested
positive for at least one high-risk type (HPV 16, 18, 31,33, 35, 39,
45, 51, 52, 56, 58, 59, 68), 704 (12.3%) tested positive for only low-
risk types, and 4292 (75.3%) tested negative for HPV.
Case–control study subjects
Subjects for this study were drawn from the 8582 women in the
Guanacaste study with an interview and final diagnosis (Figure 1).
Women who were perimenopausal (reported they were no longer
having periods and had 1 year or less since their last menstrual
period), taking exogenous hormones (93% of users were using oral
contraceptives) in the month before blood was drawn, missing
data, or who had fewer than two vial of plasma remaining in
storage were excluded.
All 110 women diagnosed with XCIN 2, who met the eligibility
requirements, were chosen as cases. There were 76 cases with
histologically confirmed CIN 2-3, nine cases with CIN 2–3 defined
by reviewed and confirmed cytology, eight cases with invasive
cervical cancer found during screening, and 17 cases with invasive
cervical cancer identified in hospitals. Two sets of controls were
matched to cases, each in a 2:1 ratio. The first set of controls,
hereafter referred to as random controls, was chosen from the 6430
women with neither CIN 2–3 nor invasive cancer. The second set
of controls, HPV-positive controls, was chosen from the pool of
noncases and nonrandom controls, who had PCR results indicat-
ing a high-risk HPV type (n¼384). All controls were frequency
matched to cases by 5- or 10-year age group and menopausal
status. Premenopausal controls were further matched to cases by
days since the last menstrual period, and postmenopausal controls
were further matched to cases by years since menopause.
10 769 eligible
10 077 interviewed 
8582 pelvic exam  583 virgins 
291 refused pelvic or problems 
621 hysterectomy 
6540 eligible for case−control  1883 current hormone users 
105 perimenopausal 
10 missing information 
44 plasma unavailable 
110 cases  6430 noncases
6210 noncases
nonrandom controls 
220 random controls 
3501 negative for high−risk HPV
2325 not tested by PCR at the 
time of selection 
220 HPV + controls 
384 HPV+ high risk 
11 742 enumerated 
84 no informed consent 
308 pregnant 
56 physically incapacitated
42 dead 
514 moved away
120 refused 
555 failed to show up 
17 other
31 invasive cancers 
Figure 1 Study subject selection.
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was as follows: 108 matched perfectly on days since the last
menstrual period and age, and 10 matched within 3 days since the
last menstrual period and 5 years of age. In all, 118 premenopausal
HPV-positive controls matched to cases within 3 days since the last
menstrual period. Altogether, 96 of the 118 matched within 5 years
of age and 22 within 10 years of age. Eight premenopausal cases
reported greater than 40 days since their last menstrual period, and
were matched to 16 random and 16 HPV-positive controls with
greater than 40 days since their last menstrual period. Among
postmenopausal women, 73 random controls matched perfectly on
years since menopause and age. The remaining 13 random
controls matched within 3 years since menopause and 5 years of
age. Of the 86 HPV-positive postmenopausal controls, 55 matched
within 3 years since menopause and 5 years of age, 22 matched
within 3 years of menopause and 10 years of age, and the
remaining nine matched within 12 years since menopause and 10
years of age.
The final control groups contained the following numbers of
CIN1/histologic atypia: premenopausal random n¼6, premeno-
pausal HPV-positive n¼36, postmenopausal random n¼0,
postmenopausal HPV-positive n¼6.
Hormone assays
Plasma samples were shipped on ice to Esoterix (Endocrine
Sciences, Calabasas Hills, CA, USA) for hormone analysis using in-
house methods. Briefly, oestradiol, oestrone, and progesterone
were measured using radioimmunoassay (RIA) following hexa-
ne:ethyl acetate extraction and column chromatography. Oestrone
sulphate was measured similarly following overnight incubation
with a sulphatase. Sex hormone-binding globulin was measured
using a ‘sandwich’ immunoradiometric assay (IRMA), utilising a
solid-phase capture antibody and a label antibody in the presence
of calcium. Sex hormone-binding globulin is the major transport
protein of oestradiol, and is thus inversely related to free
oestradiol, the fraction of oestradiol that is not bound and thus
is most biologically active. Free oestradiol was estimated by a
method proposed by Sodergard et al (1982), using the total
oestradiol measure, the SHBG measure, and assuming an albumin
level of 43gl
 1 (Vermeulen et al, 1999). Dehydroepiandrosterone
sulphate was measured by RIA following enzymolysis of the
sulphate group. Laboratory personnel were blinded to case–
control status of the samples. Repeated testing of six samples
inserted blindly into each batch of samples resulted in the
following overall coefficients of variation for the assays: SHBG
6.0%, oestradiol 16.9%, oestrone 15.3%, oestrone sulphate 15.5%,
progesterone 17.5%, and DHEAS 8.3%. The lower limits of
detection of the hormone assays were as follows: SHBG
20nmoll
 1, oestradiol 5pgml
 1, oestrone 5pgml
 1, oestrone
sulphate 100pgml
 1, DHEAS 10mgdl
 1, and progesterone
100pgml
 1. Postmenopausal progesterone levels are not pre-
sented.
Statistical analysis
Data were analysed in four groups based on menopausal status and
two sets of controls. The median hormone levels in cases and
controls were compared using a nonparametric k-sample test
(StataCorp, 2001). Hormone values were categorised into thirds
based on the distribution in the random controls, separately for
premenopausal and postmenopausal women. Relative risks were
estimated by odds ratios obtained from unconditional logistic
regression analysis. Relative risks obtained using conditional
logistic regression were similar to those from unconditional
logistic regression. Only the unconditional logistic regression
results are shown. Tests for trend were obtained by assigning
ordinal values to hormone tertiles and treating them as continuous
variables in the model. All logistic models were adjusted for
matching variables. A common model was determined for each
analytic group. The common model was adjusted for factors that
confounded the beta coefficient relating any single hormone and
the outcome by 10% or more. Variables considered as potentially
confounding factors included reproductive factors (number of
pregnancies, live births, still births, miscarriages, abortions,
cesarean sections, age at first pregnancy, age at menarche, oral
and injectable contraceptive use, intrauterine device use, and tubal
ligation), sexual behaviour, and HPV-associated variables (lifetime
number of sexual partners, number of sexual partners in the last
year, age at first intercourse, yeast infections, other sexually
transmitted diseases, hand or foot warts), socioeconomic status
variables (marital status, income, education, and number of
household amenities), smoking variables, and Pap smear history.
To further control for the cyclic variation of oestrogens during
the menstrual cycle in premenopausal women, we attempted to
capture the midluteal rise of oestrogens by repeating analyses
restricted to women thought to be in the luteal phase of their
menstrual cycle based on having progesterone levels greater than
2000pgml
 1 or having 17–23 days since the start of their last
menstrual period.
To examine whether the results of the study were biased by
inclusion of invasive cervical cancers affecting circulating hor-
mone levels, the median hormone levels were compared in cases
with invasive cervical cancer and cases with CIN 2-3. Additionally,
the data were analysed with and without subjects with invasive
cervical cancer.
RESULTS
Premenopausal cases and controls were similar with respect to
age, history of oral contraceptive use, lifetime number of Pap
smears, and income (Table 1). A somewhat lower proportion of
cases than random controls had undergone a tubal ligation. Cases
had a greater number of lifetime sexual partners, and were much
more likely to test HPV-positive than random controls. On
average, the cases had more live births and were more likely to
smoke than HPV-positive controls.
Postmenopausal cases and controls were of similar age, and
were also similar regarding the prior use of oral contraceptives,
history of tubal ligation, number of lifetime sexual partners, and
years since menopause (Table 2). The cases were slightly more
likely to have smoked, and were more likely to be HPV-positive
than random controls. Cases had slightly more live births, and
were somewhat less likely to have had a Pap smear and more likely
to have smoked than HPV-positive controls.
There were no statistically significant differences in median
hormone levels between cases and controls (Tables 3 and 4).
However, progesterone levels were higher in premenopausal cases
than in either random or HPV-positive controls. Among
postmenopausal women, oestrone and DHEAS levels were lower
in cases than in both sets of controls. Median hormone levels were
similar in cases with CIN 2–3 and cases with invasive cancer (data
not shown). With the exception of DHEAS levels, which were
significantly higher in premenopausal HPV-positive controls than
in premenopausal random controls, hormone levels were similar in
both control groups among both premenopausal and postmeno-
pausal women (Tables 3 and 4).
T a b l e s5a n d6p r e s e n tt h er i s ko fXCIN 2 associated with hormone
and SHBG levels in pre- and postmenopausal women, respectively. In
premenopausal women, no statistically significant associations were
seen between XCIN 2 and categories of plasma levels of the various
hormones and SHBG (Table 5). Increasing risk of XCIN 2 in women
with higher levels of SHBG was suggested, particularly in analyses
using HPV-positive controls. Women with higher levels of free
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XCIN 2 relative to women with lower levels.
Among postmenopausal women, there was no clear trend of
increasing or decreasing risk of XCIN 2 with increasing plasma
levels of hormones or SHBG (Table 6), although there was a
suggestion of decreasing risk of XCIN 2 in women with higher
levels of oestrone or DHEAS in analyses using random and HPV-
positive controls. In analyses using HPV-positive controls, women
with moderate oestradiol levels were at a significantly elevated risk
relative to women with low levels (OR¼2.95, 95% CI 1.1–4.3), but
a trend of increased risk with higher oestradiol level was not
observed.
Among the 31 premenopausal cases, 61 random, and 61 HPV-
positive controls, who donated blood during the luteal phase of
their menstrual cycle, no significant associations between the
measured hormones and risk of XCIN 2 were observed (Table 7).
As in the main analysis, a decreased risk of XCIN 2 in women with
the highest levels of oestrogens relative to women with the lowest
levels was only suggested.
Excluding subjects with invasive cervical cancer to assess the
potential bias due to disease effects had no substantial effect on the
findings (data not shown). Eight premenopausal cases and 32
matched controls reported more than 40 days since their last
menstrual period. Exclusion of these women, mostly lactating, had
no substantial effect on the results (data not shown).
DISCUSSION
Plasma levels of SHBG, oestradiol, oestrone, oestrone sulphate,
DHEAS, and progesterone were not significantly related to the risk
of XCIN2 in this study. To our knowledge, this is the first
Table 1 Characteristics of the premenopausal study population
Characteristic
Cases
(N¼67)
Random
controls
(N¼134)
HPV+controls
(N¼134)
Age
a
Mean7s.d.
(range)
34.376.9
(19–48)
34.676.6
(19–49)
33.477.4
(18–50)
Live births
0–2 18 27.7 36 27.7 47 36.7
3–4 24 36.9 54 41.5 56 43.8
5–7 18 27.7 30 23.1 16 12.5
X8 5 7.7 10 7.7 9 7.0
Oral contraceptive use
Never 17 25.4 34 25.4 36 26.9
o2 years 20 29.9 34 25.4 47 35.1
2–4 years 14 20.9 33 24.6 24 17.9
X5 years 16 23.9 33 24.6 27 20.2
Lifetime sexual partners
1 23 34.3 65 48.5 52 38.8
2–3 27 40.3 45 33.6 58 43.3
X4 17 25.4 24 17.9 24 17.9
Lifetime Pap smears
0 8 11.9 7 5.2 12 9.0
1–2 14 20.9 30 22.4 34 25.4
3–5 21 31.3 51 38.1 46 34.3
X6 24 35.8 46 34.3 42 31.3
Smoking
Never 55 82.1 117 87.3 126 94.0
Ever 12 17.9 17 12.7 8 6.0
Tubal ligation
Never 47 70.2 78 58.2 94 70.2
o7 years ago 15 22.4 28 20.9 25 18.7
X7 years ago 5 7.5 28 20.9 15 11.2
Income (colones/year)
p14999 12 17.9 27 20.2 26 19.4
15000–24999 19 28.4 27 20.2 29 21.6
25000–44999 18 26.9 40 29.9 35 26.1
X45000 17 25.4 35 26.1 39 29.1
Unknown 1 1.5 5 3.7 5 3.7
HPV status
a
High risk 58 86.6 16 11.9 134 100.0
Low risk 4 6.0 25 18.7 0 0
Negative 5 7.5 93 69.4 0 0
aMatching factor.
Table 2 Characteristics of the postmenopausal study population
Characteristic
Cases
(N¼43)
Random
controls
(N¼86)
HPV+controls
(N¼86)
Age
a
Mean7s.d.
(range)
63.8710.0
(45–86)
63.879.7
(45–86)
64.777.0
(45–85)
Live births
0–2 1 2.3 9 11.4 11 13.3
3–4 6 14.0 6 7.6 12 14.5
5–7 15 34.9 24 30.4 16 19.3
X8 21 48.8 40 50.6 44 53.0
Oral contraceptive use
Never 38 88.4 67 77.9 71 82.6
o2 years 2 4.7 3 3.5 5 5.8
2–4 years 1 2.3 9 10.5 7 8.1
X5 years 2 4.7 7 8.1 3 3.5
Lifetime sexual partners
1 17 39.5 45 52.3 34 39.5
2–3 18 41.8 31 36.1 37 43.0
X4 8 18.6 10 11.6 15 17.4
Lifetime Pap smears
0 13 30.2 25 29.1 20 23.3
1–2 17 39.5 18 20.9 37 43.0
3–5 8 18.6 25 29.1 19 22.1
X6 5 11.6 18 20.9 10 11.6
Years since menopause
a
Mean7s.d. (range) 13.971.7 (10–18) 13.671.6 (9–17) 14.271.9 (10–18)
Smoking
Never 30 69.8 71 82.6 70 81.4
Ever 13 30.2 15 17.4 16 18.6
Tubal ligation
Never 40 93.0 84 97.7 84 97.7
Ever 3 7.0 2 2.3 2 2.3
Income (colones/year)
p14999 17 39.5 49 57.0 46 53.5
15000–24999 8 18.6 13 15.1 16 18.6
25000–44999 9 20.9 8 9.3 12 14.0
X45000 1 2.3 8 9.3 4 4.7
Unknown 8 18.6 8 9.3 8 9.3
HPV status
a
High risk 34 79.1 8 9.3 86 100.0
Low risk 6 14.0 21 24.4 0 0
Negative 3 7.0 57 66.3 0 0
aMatching factor.
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and XCIN2, and, to the extent that associations were observed,
they conflict with our initial hypothesis that elevated levels
increase the risk of cervical neoplasia.
Since multiparity and oral contraceptive use are associated both
with elevated circulating hormone levels and with an increased risk
of cervical cancer, we hypothesised that high physiologic oestrogen
levels would adversely affect cervical carcinogenesis (Castellsague
and Munoz, 2003; Smith et al, 2003). Results of laboratory studies
suggest several different bases for such an association. In studies of
cervical cells, oestradiol has been shown to upregulate the
transcription of HPV E6 and E7 genes, and to stimulate the
growth of HPV-positive cell lines in the absence of E6 and E7
upregulation (Mitrani-Rosenbaum et al, 1989; Chen et al, 1996).
Studies of HPV-positive transgenic mice that express HPV 16
oncogenes in their basal keratinocytes have shown that chronic
exposure to oestradiol is necessary for the induction of cervical
tumours. Exposure to 0.05mg oestradiol for 60 days induced
tumours at the transformation zone of the mice, even though E6
and E7 levels remained low (Arbeit et al, 1996; Elson et al, 2000). A
previous study in China compared the unadjusted mean hormone
levels in 51 postmenopausal cervical cancer cases and 52
postmenopausal controls (Zheng, 1990). The study found higher
levels of oestradiol (91.2pgml
 1 in cases, 81.1pgml
 1 in controls)
and oestrone (116.1pgml
 1 in cases, 90.2pgml
 1 in controls) in
cases than in controls. In contrast, our findings for total oestradiol,
SHBG, oestrone, and free oestradiol fail to support the notion that
high levels of oestrogens increase the risk of cervical cancer.
Rather, the observed trends of increased risk in women with
increasing levels of SHBG and decreased risk in women with
increasing levels of oestradiol, free oestradiol, and oestrone imply
that high levels of oestrogens may, if anything, be associated with a
decreased risk of XCIN 2.
The presence of progesterone has been hypothesised to increase
the risk of XCIN 2 by inducing transformation of cells by HPV-16
and upregulating HPV expression in cell lines via binding and
activation of glucocorticoid response elements found on the
upstream regulatory region of the virus (Pater et al, 1994). Use of
injectible contraceptives, typically consisting of progesterone only,
has also been associated with an increased risk of cervical cancer
(Herrero et al, 1990; Hildesheim et al, 2001). Though premeno-
Table 3 Median hormone levels in premenopausal women
Cases Ctrls HPV+Ctrls
Hormone N
Median
(IQR
a) N
Median
(IQR) N
Median
(IQR)
SHBG
(nmoll
 1)
67 80.3 (60.0) 134 70.9 (52.9) 134 75.4 (54.2)
Oestradiol
(pgml
 1)
66 88.3 (91.5) 132 87.5 (110.7) 133 93.5 (98.0)
Oestrone
(pgml
 1)
66 68.0 (51.0) 122 73.0 (51.5) 126 72.0 (53.0)
Oestrone
sulphate
(pgml
 1)
64 1738 (2324) 131 1776 (1536) 129 1941 (1921)
DHEAS
(mgdl
 1)
67 104.1 (143.0) 134 94.5 (120.0)
b 134 109.0 (144.5)
b
Progesterone
(pgml
 1)
66 1105 (6387) 134 681 (6253) 133 678 (6483)
aIQR¼interquartile range.
bP-value¼0.04 for comparison of random controls to
HPV-positive controls.
Table 4 Median hormone levels in postmenopausal women
a
Cases Ctrls HPV+ Ctrls
Hormone N
Median
(IQR
b) N
Median
(IQR) N
Median
(IQR)
SHBG
(nmoll
 1)
43 76.4 (70.4) 86 81.1 (49.7) 86 69.3 (43.1)
Oestradiol
(pgml
 1)
41 6.5 (6.0) 86 7.0 (7.0) 85 6.5 (7.0)
Oestrone
(pgml
 1)
40 15.5 (16.5) 85 20.5 (17.0) 84 19.5 (21.0)
Oestrone
sulphate
(pgml
 1)
41 447 (346) 83 425 (280) 86 453 (271)
DHEAS
(mgdl
 1)
43 37.5 (32.5) 86 45.0 (48.5) 86 42.5 (41.5)
aP-value40.05 for all comparisons.
bIQR¼interquartile range.
Table 5 Risk of XCIN 2 associated with hormone levels in
premenopausal women
Random controls HPV-positive controls
Cases Ctrls OR
a 95% CI Cases Ctrls OR
b 95% CI
SHBG
p55.6nmoll
 1 16 44 1.0 16 45 1.0
55.7–90.1 21 45 1.1 (0.5–2.5) 21 41 1.3 (0.6–3.0)
X90.2 30 45 1.6 (0.7–3.4) 30 48 1.7 (0.8–3.7)
P-trend 0.23 0.16
Oestradiol
p71.5pgml
 1 24 44 1.0 23 47 1.0
71.6–133.0 23 44 1.3 (0.6–2.7) 24 46 1.3 (0.6–2.8)
X133.1 19 44 0.7 (0.3–1.6) 19 40 0.9 (0.4–2.1)
P-trend 0.39 0.87
Free oestradiol
p1.41pgml
 1 28 42 1.0 28 48 1.0
1.42–2.50 20 43 0.8 (0.4–1.7) 20 41 0.9 (0.4–1.9)
X2.51 17 42 0.5 (0.2–1.2) 17 34 0.8 (0.4–1.9)
P-trend 0.13 0.63
Oestrone
p62.0pgml
 1 27 41 1.0 27 47 1.0
62.1–90.0 16 40 0.6 (0.3–1.3) 16 40 0.7 (0.3–1.7)
X90.1 19 41 0.5 (0.2–1.2) 19 39 0.9 (0.4–2.0)
P-trend 0.13 0.77
Oestrone sulphate
p1254pgml
 1 20 43 1.0 20 37 1.0
1255–2287 25 44 1.3 (0.6–2.8) 25 42 1.2 (0.5–2.6)
X2288 19 44 0.9 (0.4–1.9) 19 50 0.7 (0.3–1.7)
P-trend 0.74 0.45
DHEAS
p78.5mgdl
 1 22 44 1.0 22 32 1.0
78.6–114.5 18 45 0.8 (0.3–1.8) 18 39 0.7 (0.3–1.6)
X114.6 27 45 1.2 (0.6–2.7) 27 63 0.7 (0.3–1.5)
P-trend 0.61 0.41
Progesterone
p320pgml
 1 18 44 1.0 18 44 1.0
321–2707 26 45 1.4 (0.7–3.2) 26 46 1.4 (0.6–3.1)
X2708 22 45 1.3 (0.6–3.1) 22 43 1.5 (0.6–3.4)
P-trend 0.53 0.38
aAdjusted for age (18–25, 26–30, 31–35, 36–40, 41–45, 46–50 years), days since
last menstrual period (continuous), tubal ligation (never, o 7 years ago, 7+ years
ago) and number of lifetime sexual partners (1, 2–3, 4+).
bAdjusted for age (18–25,
26–30, 31–35, 36–40, 41–45, 46–50 years), days since last menstrual period
(continuous) and smoking (never, ever).
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ypausal women with higher progesterone levels were at a somewhat
greater risk of XCIN 2 than women with lower levels, we did not
observe clear trends of increasing risk with increasing progester-
one level.
The ideal study of the role of hormones and cervical cancer
would be prospective, with multiple measures of hormones over
time and before detection of invasive disease. Such a study,
however, would be extraordinarily difficult to implement in part
due to the low incidence of this malignancy and because current
medical practice requires intervention at earlier stages. In the light
of these difficulties, a case–control study design is the reasonable
first approach to explore the role of plasma hormones in cervical
carcinogenesis, despite the familiar concerns about unreliable
results stemming from biomarkers that may be influenced by the
disease under study. We used what is arguably the optimal case
group, namely confirmed precancer (CIN 2-3). The cases, identified
through intensive screening of a large sample of the Guanacaste
population and among Guanacaste residents with invasive cancer
presenting at regional and tertiary care hospitals, comprised an
unbiased sample of Guanacaste women who developed XCIN 2
during enrollment. This surrogate end point poses a high
cumulative risk of subsequent invasion, but is still intraepithelial
and, thus, unlikely to affect the systemic hormone levels. Using
subjects identified in a well-defined, large cohort allowed us to
select controls that were representative of the underlying population
from which most of the cases arose. DNA testing of study subjects
allowed selection of a second control group of HPV-positive
women, to assess whether hormones were related to the risk of
XCIN 2, given exposure to HPV. We were able to measure a panel
of five hormones and SHBG using assays with good reproducibility.
Several issues may have contributed to our finding of no
association between sex hormones and XCIN 2. Even in a large
population-based study such as this, the number of cases of XCIN
2 available for analysis was small, particularly after separating
subjects by menopausal status. Thus, we were not well-powered to
detect modest risks. Despite our focus on CIN 2 and 3, the
neoplasia may have influenced plasma hormone levels. However,
median hormone levels were similar among cases with invasive
disease and cases with CIN 2-3, results were similar after exclusion
of invasive cases, and we reiterate our belief that intraepithelial
lesions are unlikely to affect the circulating hormone levels.
Finally, the use of a single blood sample at one point in time to
characterise the long-term hormonal environment of a woman
may be problematic. Endogenous hormone levels are known to
vary throughout a woman’s lifetime, in response to various factors
such as changes in body weight, exogenous hormone use, and
during menstrual cycling. We matched controls to cases by age,
years since menopause (postmenopausal) and days since the last
menstrual cycle (premenopausal), to account for this. Analyses
including all premenopausal women and those restricted to women
in the luteal phase of the cycle yielded similar results. However, we
lacked information to control for other sources of variation in
hormones over time, such as menstrual cycle length. Our inability
to account for sources of hormone variability may have attenuated
the risks and limited the ability of the study to detect some true
associations (Armstrong et al, 1992).
Table 6 Risk of XCIN 2 associated with hormone levels in
postmenopausal women
Random controls HPV-positive controls
Cases Ctrls OR
a 95% CI Cases Ctrls OR
b 95% CI
SHBG
p62.3nmoll
 1 19 29 1.0 19 34 1.0
62.4–96.8 8 28 0.4 (0.1–1.3) 8 33 0.5 (0.2–1.4)
X96.9 16 29 0.7 (0.3–1.9) 16 19 1.5 (0.6–4.3)
P trend 0.50 0.51
Oestradiol
p2.5pgml
 1 11 30 1.0 11 33 1.0
5–8.5 20 27 1.9 (0.7–5.2) 20 26 3.0 (1.1–4.3)
X8.6 10 29 1.0 (0.3–2.9) 10 26 1.1 (0.4–3.5)
P-trend 1.0 0.76
Free oestradiol
p0.149pgml
 1 13 19 1.0 13 15 1.0
0.15–0.209 10 18 1.1 (0.3–3.7) 10 15 2.5 (0.5–11.7)
X0.21 7 19 0.6 (0.2–2.0) 7 22 0.3 (0.1–1.2)
P-trend 0.39 0.09
Oestrone
p14.5pgml
 1 18 28 1.0 18 30 1.0
14.6–27.5 12 27 0.9 (0.3–2.5) 12 28 0.7 (0.3–2.0)
X27.6 10 30 0.5 (0.2–1.5) 10 26 0.6 (0.2–1.7)
P-trend 0.23 0.34
Oestrone sulphate
p370pgml
 1 15 27 1.0 15 28 1.0
371–583 13 28 0.6 (0.2–1.7) 13 34 0.9 (0.3–2.6)
X584 13 28 0.8 (0.3–2.2) 13 24 0.9 (0.3–2.7)
P-trend 0.68 0.90
DHEAS
p32mgdl
 1 19 29 1.0 19 31 1.0
33–61 16 28 0.9 (0.3–2.2) 16 29 0.9 (0.3–2.4)
X62 8 29 0.5 (0.2–1.3) 8 26 0.4 (0.1–1.2)
P-trend 0.17 0.11
aAdjusted for age (45–59, 60–69, 70+ years), years since menopause (continuous),
number of Pap smears (0, 1–2, 3–5, 6+), smoking (never, ever), and income
(o14999, 15000–24999, 25000+, unknown).
bAdjusted for age (45–59, 60–69,
70+ years), years since menopause (continuous), number of live births (0–4, 5–7,
8+), smoking (never, ever), and age at menarche (o12, 13–14, 15+).
Table 7 Risk of XCIN 2 associated with oestrogen levels in women in
the luteal phase
Random controls HPV-positive controls
Cases Ctrls OR
a 95% CI Cases Ctrls OR
b 95% CI
Oestradiol
p71.5pgml
 1 6 10 1.0 6 8 1.0
71.6–133.0 15 27 1.0 (0.3–3.8) 15 30 1.0 (0.2–4.4)
X133.1 10 24 0.5 (0.1–2.0) 10 22 0.8 (0.2–3.8)
P-trend 0.24 0.72
Free oestradiol
p1.41 8 9 1.0 8 9 1.0
1.42–2.50 12 25 0.5 (0.1–1.7) 12 31 0.4 (0.1–1.7)
X2.51 11 24 0.4 (0.1–1.4) 11 15 1.2 (0.3–5.0)
P-trend 0.18 0.60
Oestrone
p62.0pgml
 1 7 12 1.0 7 9 1.0
62.1–90.0 9 19 0.7 (0.2–3.0) 9 18 0.9 (0.2–4.1)
X90.1 11 21 0.7 (0.2–2.8) 11 27 0.6 (0.1–2.5)
P-trend 0.68 0.40
Oestrone sulphate
p1254pgml
 1 6 11 1.0 6 10 1.0
1255–2287 14 21 1.4 (0.4–5.3) 14 19 1.4 (0.3–6.1)
X2288 9 26 0.7 (0.2–2.6) 9 29 0.6 (0.1–2.8)
P-trend 0.46 0.27
aAdjusted for age (18–25, 26–30, 31–35, 36–40, 41+ years), days since last
menstrual period (continuous), tubal ligation (never, o7 years ago, 7+ years ago) and
number of lifetime sexual partners (1, 2–3, 4+).
bAdjusted for age (18–25, 26–30,
31–35, 36–40, 41+ years), days since last menstrual period (continuous) and
smoking (never, ever).
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yIn conclusion, the data fail to support hypotheses that elevated
plasma levels of endogenous oestrogens or progesterone increase
the risk of cervical neoplasia. If associations between endogenous
hormone levels and the risk of cervical cancer truly do exist, they
are likely to be modest in size. In order to reliably document such
associations, future studies of squamous cervical neoplasia would
require both very large numbers of subjects and a means of more
accurately characterising women’s long-term hormonal milieu.
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